FDA approves anti-clotting drug Savaysa

The U.S. Food and Drug Administration today approved the anti-clotting drug Savaysa (edoxaban tablets) to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem.
Source: Food and Drug Administration - Category: American Health Source Type: news